从致命疾病到功能性治愈:慢性髓性白血病酪氨酸激酶抑制25年
慢性髓性白血病由费城染色体产生的BCR::ABL1融合基因驱动,酪氨酸激酶抑制剂(TKI)将其治疗从非特异性方案转变为精准靶向治疗范式。伊马替尼为首个TKI,后续代际TKI克服耐药和不耐受,使应答者生存接近一般人群,治疗目标转向生活质量和无治疗缓解(TFR)。关键停药研究显示约半数符合条件的患者可维持TFR,但TKI耐药、安全性及TFR达成率较低仍是挑战。
要点
- CML由费城染色体产生的BCR::ABL1融合基因驱动,是精准靶向治疗的范式。
- 伊马替尼为首个TKI,后续代际TKI克服耐药和不耐受,应答者生存接近一般人群。
- 关键停药研究显示约半数符合条件的患者可维持无治疗缓解(TFR)。
核心结论
- TKI使CML从致命疾病转变为可通过靶向治疗实现功能性治愈的疾病,应答者生存接近一般人群。
研究设计与样本
- 综述类,检索范围未在原文中报告。
主要发现
- 伊马替尼作为首个TKI,展示了前所未有的血液学、细胞遗传学和分子学应答,迅速成为CML标准治疗。
- 后续代际TKI被开发用于克服伊马替尼耐药和不耐受,改善了CML生存。
- 关键停药研究显示约半数符合条件的患者可维持无治疗缓解(TFR)。
临床怎么用
- 对TKI应答的CML患者,治疗目标应包括生活质量及考虑无治疗缓解(TFR)的可能性。
局限性
- TKI耐药、安全性考虑以及达成并维持TFR的患者比例相对较低仍是重要挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22. This alteration gives rise to the BCR::ABL1 fusion oncogene, whose constitutive tyrosine kinase activity promotes uncontrolled proliferation and survival of leukemic cells. The discovery of this molecular driver laid the foundation for the development of tyrosine kinase inhibitors (TKIs), which transformed CML management from treatment with non-specific modalities to establishing a new paradigm for precision oncology with targeted therapies. Imatinib, the first TKI, demonstrated unprecedented hematologic, cytogenetic, and molecular responses, rapidly becoming the standard of care in CML. Subsequent generations of TKIs were developed to overcome resistance and intolerance to imatinib. These advances improved survival in CML, bringing life expectancy close to that of the general population for the patients who respond to treatment, and shifting treatment goals towards quality of life and the possibility of treatment-free remission (TFR). Landmark discontinuation studies showed that approximately half of eligible patients can maintain TFR. Despite these achievements, important challenges remain, including TKI resistance, safety considerations, and the relatively low proportion of patients who achieve and maintain TFR. Newer-generation TKIs, combination strategies, immunomodulatory approaches, and emerging treatment modalities such as degraders offer promising avenues to further improve outcomes, expand TFR eligibility, ensure optimal quality of life, address resistance mechanisms, and render therapy available and affordable to all patients with CML worldwide.
引用
- Hochhaus A, Talpaz M, Saglio G, et al. From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. Leukemia. 2026. PMID: 42174092. doi:10.1038/s41375-026-02984-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。